EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Use of Long‐Term Monthly Basiliximab Infusions as Rescue Maintenance Immunosuppression in Pancreas Transplant Recipients

Jeanne M Chen iD, Richard S Mangus iD, Asif A Sharfuddin, John A Powelson, Muhammad S Yaqub, Oluwafisayo O Adebiyi iD, Muhammad Y Jan, Andrew J Lutz, Jonathan A Fridell iD

Clinical Transplantation · 2024

DOI: 10.1111/ctr.70050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Jeanne M Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, IU Health, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Basiliximab, Pancreas Transplantation, Immunosuppressive Agents, Graft Rejection. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This single‐center retrospective study was designed to evaluate the use of basiliximab as an alternative rescue maintenance immunosuppression in situations where standard maintenance immunosuppression is not tolerated after a pancreas transplant. All pancreas transplants performed between January 11, 2006, and January 6, 2022, were reviewed. All recipients received rabbit antithymocyte globulin (rATG) induction with tacrolimus + sirolimus maintenance for simultaneous pancreas and kidney (SPK) and additional low‐dose mycophenolic acid for pancreas transplant alone (PTA). Basiliximab 40mg IV q 4 weeks was either added to or in replacement of adjunct immunosuppression in cases of medication intolerance. All recipients who received ≥3 months of basiliximab with ≥1 year follow‐up were included. 29/557 (5.2%) recipients (5 SPK and 24 PTA) were identified. Median time to switch was 13 months. When compared 1:2 to matched controls on standard immunosuppression, there was no difference in pancreas rejection, allograft loss, or mortality. Eleven recipients had 13 episodes of pancreas rejection at a median of 28 months post conversion. Eight pancreas allografts failed at a median of 28 months post conversion, and there were five deaths—all occurring in PTA, 4/5 occurring ≥1 year after discontinuation of basiliximab. Renal allograft rejection occurred in one SPK and there was one renal allograft loss. Five PTA developed renal failure. Ten remain on basiliximab (2/5 SPK, 8/24 PTA) at a median of 44 months with good pancreas and kidney function; 4 pts > 4 years. Basiliximab can be considered an alternative rescue maintenance strategy in pancreas transplant recipients who failed other conventional agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BasiliximabPancreas TransplantationImmunosuppressive AgentsGraft RejectionGraft SurvivalHumansRetrospective StudiesMaleFemaleFollow-Up StudiesAdultMiddle AgedRecombinant Fusion ProteinsPrognosisPostoperative ComplicationsRisk FactorsImmunosuppression TherapyInfusions, IntravenousKidney Transplantation

Stichwörter der Autor:innen

basiliximabimmunosuppressionpancreas transplant

Substanzen

BasiliximabImmunosuppressive AgentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Pharmacy, IU Health, Indianapolis, Indiana, USA.
  • Department of Surgery, IU Health/Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Nephrology, IU Health/Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Jeanne M Chen, Richard S Mangus, Oluwafisayo O Adebiyi, Jonathan A Fridell

Zitieren

APA

Chen, J. M., Mangus, R. S., Sharfuddin, A. A., Powelson, J. A., Yaqub, M. S., Adebiyi, O. O., Jan, M. Y., Lutz, A. J., & Fridell, J. A. (2024). The Use of Long‐Term Monthly Basiliximab Infusions as Rescue Maintenance Immunosuppression in Pancreas Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70050

Vancouver

Chen JM, Mangus RS, Sharfuddin AA, Powelson JA, Yaqub MS, Adebiyi OO, et al. The Use of Long‐Term Monthly Basiliximab Infusions as Rescue Maintenance Immunosuppression in Pancreas Transplant Recipients. Clinical Transplantation. 2024. doi:10.1111/ctr.70050

BibTeX
@article{Chen2024,
  author = {Chen, Jeanne M and Mangus, Richard S and Sharfuddin, Asif A and Powelson, John A and Yaqub, Muhammad S and Adebiyi, Oluwafisayo O and Jan, Muhammad Y and Lutz, Andrew J and Fridell, Jonathan A},
  title = {The Use of Long‐Term Monthly Basiliximab Infusions as Rescue Maintenance Immunosuppression in Pancreas Transplant Recipients},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.70050}
}
Kostenlos starten →